Form 4: ORA insider SAR exercise and share sales reduce stake to 4,861
Rhea-AI Filing Summary
Insider activity summary: Director Stanley Stern exercised 1,210 stock appreciation rights (SARs) with an exercise price of $76.87, based on SARs that expire November 6, 2025. The exercise used the market value on the exercise date of $94.83 to determine payout, resulting in issuance of 229 common shares and a cash settlement for the remaining economic value equivalent to 981 shares. On the same day, 229 shares were sold at $94.83, and an additional 400 shares were sold on September 30, 2025 at $95.98. After these transactions, Mr. Stern beneficially owned 4,861 shares.
Positive
- Full disclosure provided on SAR exercise, share issuance, sales, prices, and resulting beneficial ownership
- Transactions reported within required Section 16 format, including exercise price, market price, and counts
Negative
- None.
Insights
TL;DR: Routine SAR exercise followed by partial sales; reduces insider stake slightly but appears to be standard liquidity activity.
The reporting shows a full exercise of 1,210 SARs at an exercise price of $76.87, with the economic spread calculated against a market price of $94.83. The filing reports both cash settlement
TL;DR: Disclosure is complete for the SAR exercise and subsequent sales; filings comply with Section 16 reporting requirements.
The Form 4 documents exercise mechanics for SARs expiring 11/06/2025 and provides prices, share counts, and resulting ownership. It notes the typical net-share/cash settlement structure where 229 shares were issued and 981 were settled as the cash equivalent. The signature by an attorney-in-fact is provided. From a governance perspective, the filing transparently reports director transactions and updated beneficial ownership to 4,861 shares.